FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
houre por roeponeo	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Hallam Trevor				2. Issuer Name and Ticker or Trading Symbol SUTRO BIOPHARMA, INC. [STRO]					5. R	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Kast) (First) (Middle) C/O SUTRO BIOPHARMA, INC., 310 UTAH AVENUE, SUITE 150			3. Date of Earliest Transaction (Month/Day/Year) 01/29/2019					X	X Officer (give title below) Other (specify below) Chief Science Officer							
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
)	(State)	(Zip)			Ta	ble I	- Non-Deriv	ative Securitie	s Acquired,	quired, Disposed of, or Beneficially Owned						
ecurity		2. Transaction Date (Month/Day/Year)	Executi any	on D	ate, if C	ode nstr.	8) (A	n) or Disposed on the str. 3, 4 and 5) (A) or	of (D) Owr Tran	(D) Owned Following Reported Transaction(s) (Instr. 3 and 4)		d	Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
		3A. Deemed Execution Date, if any	4. Transac Code	ts, ca	5. Numb of Deriv Securities Acquired or Dispo of (D)	eants, per ative es d (A) osed	6. Date Exe Expiration 1 (Month/Day	vertible securing reisable and Date	7. Title and of Underly Securities	icially Owned ies) 7. Title and Amount of Underlying Securities Securities		and Amount 8. Price of Derivative Security		ve Derivative Owners Securities Form of Derivation Owned Security Following Reported or Indire		Beneficia Ownersh (Instr. 4)
			Code	V	·	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	s) (I) (Instr. 4)			
\$ 10.45	01/29/2019		A				(1)	01/28/2029	Commor Stock	47,500	\$ 0	47,500	D			
	2. Conversion or Exercise Price of Derivative Security	Report on a separate line for each 2. Conversion or Exercise Price of Derivative Security (First) (Street) (Street) (Street) (State) (State) (State) (Authorized the price of Derivative Security	revor (First) (Middle) RO BIOPHARMA, INC., 310 UTAH E, SUITE 150 (Street) SAN FRANCISCO, CA 94080 (State) (Zip) Ecurity 2. Transaction Date (Month/Day/Year) Table II - 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	SUTRO (First) (Middle) (RO BIOPHARMA, INC., 310 UTAH (S., SUITE 150) (Street) (Street) (Street) (Street) (A. If Ame	Report on a separate line for each class of securities beneficially over the form of Exercise Price of Derivative Security Security Suttro BIO (Street) (Street) (Street) 3. Date of Ear 01/29/2019 4. If Amendment Amendment Suttraction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securities beneficially over the form of Exercise (Month/Day/Year) 2. Table II - Derivative Security Table II - Derivative Security (Month/Day/Year) (Month/Day/Year) Code V Code V	SUTRO BIOPHAI (Street) (Street) (Street) (Street) (State) (Zip) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year)) (Month/Day/Year) 2. Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year)) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Code (Instr. 8) (Code V (A)	SUTRO BIOPHARMA (First) (Middle) (Street) 3. Date of Earliest Transaction (1/29/2019) (Street) 4. If Amendment, Date Original San Francisco, CA 94080 (State) (Zip) Table II (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Report on a separate line for each class of securities beneficially owned directly of the composition of Exercise (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrants, code (Instr. 8) or Disposed of (D) (Instr. 3, 4, and 5) (Code V (A) (D)	SUTRO BIOPHARMA, INC. [S' O (First) (Middle) RO BIOPHARMA, INC., 310 UTAH E, SUITE 150 (Street) SAN FRANCISCO, CA 94080 (State) (Zip) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Instr. 8) Code V A Table II - Derivative Securities Acquired, Dispo (e.g., puts, calls, warrants, options, cor Code (Month/Day/Year) 3. Transaction In this fi displays Table II - Derivative Securities Acquired, Dispo (e.g., puts, calls, warrants, options, cor Code (Instr. 8) Code V A Code V (A) Date Expiration I Securities Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Date Exercisable Code V (A) Date Exercisable	SUTRO BIOPHARMA, INC. [STRO] (Notate) (Street) (A. Securities Acquired, Or Disposed of (Instr. 8) (Instr. 3, 4 and 5) (A) or Disposed of (Instr. 8) (Month/Day/Year) (Month/Day/Year)	SUTRO BIOPHARMA, INC. [STRO] (First) (Middle) (RO BIOPHARMA, INC., 310 UTAH (S. SUITE 150) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Street) (Stree	SUTRO BIOPHARMA, INC. [STRO] O (First) (Middle) (Storet) (Storet) SAN FRANCISCO, CA 94080 O (State) (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Code V Amount (D) Price Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3) and (Month/Day/Year) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3) and (D)	SUTRO BIOPHARMA, INC. [STRO] (Middle) (RO BIOPHARMA, INC., 310 UTAH (Street) 4. If Amendment, Date Original Filed/Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3 and 4) (A) or Price (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (A) or Disposed of (D) (Instr. 3 and 4) (B) Date Exercisable and or Date (Instr. 5) (Code V (A) (D) (D) (28/2029 (Common Date (Instr. 5)) (Code V (A) (D) (D) (28/2029 (Common Date (Instr. 5)) (Code V (A) (D) (D) (28/2029 (Common Date (Instr. 5))	SUTRO BIOPHARMA, INC. [STRO] (First) (Middle) (RO BIOPHARMA, INC., 310 UTAH (Street) (Street) (Street) (A If Amendment, Date Original FiledMonth/Day/Vear) (State) (Zip) (State) (Zip) (State) (Zip) (State) (Zip) (State) (Zip) (State) (Zip) (Month/Day/Year) (State) (Zip) (State) (Zip) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 3, 4 and 5) (Instr. 3 and 4) (Month/Day/Year) (Month/Day/Year) (Instr. 3, 4, and 5) (Instr. 3) (Instr. 4) (Inst	SUTRO BIOPHARMA, INC. [STRO] (First) (Middle) (RO BIOPHARMA, INC., 310 UTAH) (Ro BIOPHARMA,		

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Hallam Trevor C/O SUTRO BIOPHARMA, INC. 310 UTAH AVENUE, SUITE 150 SOUTH SAN FRANCISCO, CA 94080			Chief Science Officer			

Signatures

/s/ Edward C. as attorney-in-fact for Trevor Hallam	01/31/2019
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.